Iga Nephropathy

• EMA approval · 2026-04-23
  EMA Authorised: Kinpeygo (budesonide, micronised) — Stada Arzneimittel AG

  The European Medicines Agency authorised Kinpeygo, a budesonide, micronised formulation, for IgA nephropathy, with orphan designation, devel…

• EMA approval · 2025-12-08
  EMA Authorised: Filspari (sparsentan) — Vifor France

  The European Medicines Agency has authorised Filspari (sparsentan) for glomerulonephritis, including IgA nephropathy, with orphan designatio…

• FDA approval · 2024-06-05
  FDA Approved: TARPEYO — Supplemental Application (Calliditas Therapeutics AB)

  FDA approved a supplemental application for Tarpeyo (budesonide) submitted by Calliditas Therapeutics AB.

• FDA approval · 2023-12-20
  FDA Approved: TARPEYO — Supplemental Application (Calliditas Therapeutics AB)

  FDA approved a supplemental application for Tarpeyo (budesonide) submitted by Calliditas Therapeutics AB.

• FDA approval · 2023-10-18
  FDA Approved: FILSPARI — Supplemental Application (Travere Therapeutics, Inc.)

  The FDA has a supplemental application (AP) for Filspari (sparsentan) from Travere Therapeutics, Inc., currently under regulatory review. Th…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2021-12-15
  FDA Approved: TARPEYO — Original Application (Calliditas Therapeutics AB)

  FDA approved Tarpeyo (budesonide) from Calliditas Therapeutics AB through an original application for the treatment of IgA nephropathy. This…